Ethical Principles

The four principles of biomedical ethics (autonomy, beneficence, nonmaleficence, and justice) form the foundation of ethical reasoning in genetic counseling. These principles frequently conflict in practice, and sound ethical reasoning requires identifying which are in tension before determining which should take precedence in a given clinical context.

• Autonomy: The patient's right to make informed, voluntary decisions about their own care. In genetic counseling, this is expressed through informed consent, nondirective counseling in reproductive decisions, and the right to decline testing. Autonomy is generally the dominant principle in genetic counseling.
• Beneficence: The obligation to act in the patient's best interest. This includes providing accurate information, recommending surveillance for actionable conditions, and facilitating access to appropriate care. Beneficence may conflict with autonomy when a patient makes a decision the provider believes is harmful.
• Nonmaleficence: The obligation to "do no harm." In genetics, this includes avoiding unnecessary testing that could cause psychological distress, being cautious about testing minors for adult-onset conditions, and not disclosing information that the patient has declined to receive (e.g., fetal sex when not requested).
• Justice: Fair distribution of benefits, risks, and costs. In genetics, justice concerns include equitable access to testing regardless of socioeconomic status, addressing disparities in variant databases (which underrepresent non-European populations), and ensuring research benefits are shared across communities.
• Conflicts between principles: Two or more principles often collide in practice:
  • Duty to warn vs. patient autonomy: If a patient refuses to inform at-risk relatives of a result (e.g., a BRCA1 pathogenic variant), the counselor faces a conflict between respecting the patient's confidentiality (autonomy) and the potential benefit to the relative (beneficence). In most U.S. jurisdictions, the counselor cannot override patient confidentiality to warn relatives, though some legal cases (e.g., Pate v. Threlkel, Safer v. Pack) have recognized a duty to warn in limited circumstances.
  • Patient autonomy vs. beneficence: A parent requests predictive testing of their 5-year-old for Huntington disease. The child cannot provide autonomous consent, and the test offers no medical benefit in childhood but could cause significant psychological harm. Here, nonmaleficence and the child's future autonomy override the parent's request.
  • Justice vs. resource constraints: A patient without insurance needs exome sequencing that could change management, but the institution cannot absorb the cost. Justice demands access, but practical constraints exist.
• Testing minors for adult-onset conditions: Major professional organizations (ASHG, ACMG, NSGC, AAP) recommend against predictive testing of minors for adult-onset conditions when no medical intervention is available in childhood. This preserves the child's future autonomy: the right to decide as an adult whether they want to know. Exceptions include conditions with childhood-onset surveillance recommendations (e.g., FAP, Li-Fraumeni syndrome).
• Testing minors for carrier status: Generally deferred until the individual can make their own reproductive decisions. Carrier status has no medical implications in childhood and should be the individual's choice to learn.
• Veracity (truthfulness): The obligation to tell the truth. Genetic counselors should not withhold or distort information, even when the truth is difficult. This principle underlies full disclosure of results, limitations of testing, and honest discussions of prognosis.

• A man diagnosed with Lynch syndrome refuses to tell his three siblings, who are each at 50% risk. His sister has not had a colonoscopy in years. The counselor should strongly encourage disclosure, offer to help facilitate the conversation, and provide a family letter. However, in most jurisdictions, the counselor cannot contact the siblings directly without the patient's consent. Document the conversation thoroughly.
• Parents request whole exome sequencing on their healthy 8-year-old "so we know everything." This raises concerns about nonmaleficence (psychological harm from learning about adult-onset disease risk), the child's future autonomy, and the potential for incidental findings. The counselor should discuss these issues and generally recommend against broad predictive testing in a healthy child without clinical indication.
• A 16-year-old with a family history of BRCA1 asks to be tested. She is mature and articulate. However, BRCA-related cancer surveillance does not begin until age 25 (breast MRI) and mastectomy/oophorectomy discussions are for adults. Testing at 16 offers no immediate medical benefit and could cause psychological harm. The recommendation is to defer testing until age 18 or older, when the individual can provide fully autonomous consent and results would be proximate to the start of surveillance.
• A clinical trial for a novel gene therapy excludes patients from a rural, predominantly Indigenous community due to the distance from the study site. This raises justice concerns: research benefits should be accessible to all populations, particularly those historically underrepresented.